Neural Therapeutics wins CSE conditional approval for Hanf.com acquisition deal

PUBT · 1d ago
Neural Therapeutics wins CSE conditional approval for Hanf.com acquisition deal
  • Neural Therapeutics received conditional CSE clearance to list shares tied to its planned acquisition of remaining equity in CWE European Holdings.
  • The deal would make CWE, operator of Hanf.com in Germany, a wholly owned subsidiary; Neural plans to rename to Hanf.com.
  • Conditions include completing the concurrent financing, required escrow arrangements, and SEDAR+ filings; the CSE will set a post-close trading date.
  • Neural shareholders backed the transaction on May 25, 2026, including a proposed share consolidation and the Hanf.com name change.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neural Therapeutics Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608141701NEWSFILECNPR____20260814_309746_1) on August 14, 2026, and is solely responsible for the information contained therein.